CLINICAL_TRIALS
trial_result
· 2010-05-27
Clinical Trial Update: Sorafenib Dose Escalation in Renal Cell Carcinoma [Phase 2]
Summary
A Phase 2 dose-escalation study of sorafenib in renal cell carcinoma completed, with results posted May 27, 2010.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2010-05-27